Vol 21 No 3 (2015)

Vol 21 No 3 (2015)

Published July 1, 2015

Commentary

Menghis Bairu
Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs
PDF
Peter J. Pitts
The Globetrotting Regulator
PDF
Peter Pitts
FDA: Is Off-Label on the Table?
PDF
Henry I Miller, Graham Brookes
A ‘Genetically Engineered’ Label: Way More Expensive Than You Think
PDF

Articles

Clifford S Mintz, Evan Nison, AJ Fabrizio
Cannabis-Derived Pharmaceuticals
PDF
Kenneth Fernald, Ruud Hoeben, Eric Claassen
Venture Capitalists as gatekeepers for Biotechnological Innovation
PDF

From the Boardroom

Ian C. Clift
BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision
PDF

Legal and Regulatory Updates

Henry Elliott
EU Legal & Regulatory Update – May 2015
PDF

Conference Report

Vasu Pestonjamasp
Innovation Landscape, Deal-making Strategies and Success Stories
PDF